Fluidic Analytics Raises $31 Million To Develop Protein Analysis Tools

By Dan Anderson ● November 29, 2018

Fluidic Analytics is a company that develops protein analysis tools that transforms the understanding of how the biological world operates that has announced it has raised $31 million. This financing round was led by Draper Esprit, a pan-European venture firm which invests in companies at the early and growth stages. New investors Delin Ventures and BGF also participated in this round. And existing investors IQ Capital and Amadeus Capital Partners also joined.

Fluidic Analytics plans to use the funding to continue the commercial roll-out of the company’s lab tools pipeline and develop further high-value clinical applications of its technology.

“This financing will power the global commercial launch of our Fluidity One system and enable our team to bring our next two lab-tools products to market,” said Fluidic Analytics CEO Andrew Lynn in a statement. “It will also allow us to advance a number of high-potential clinical applications that could help us make an even bigger impact on the world. We are delighted to be working with investors who share our vision of helping people everywhere make better decisions about how diseases are diagnosed, treatments are developed, and personal well-being is maintained.”

In order to develop new methods for matching the right treatment to the right patient at the right time, it is crucial to understand proteins and their behavior. The understanding of diseases and health in real time has been limited due to the shortcomings of tools for protein characterization.

Fluidic Analytics’ products uses a proprietary technology platform from the University of Cambridge. The platform was designed to give deep insights into the way that proteins fold and interact by characterizing them in solution as they exist in the body.

These products have the potential for researchers to understand the mechanisms underlying conditions such as Alzheimer’s disease. It will also enable pharmaceutical companies to develop more effective drugs and help patients gain access to more accurate diagnostics in the clinic.

“We are always looking for the brightest thinkers with the best teams and technology to back for the long-term, and we have found that in Fluidic Analytics,” added Draper Esprit venture partner Vishal Gulati. “The progress that Fluidic has made to date has been exemplary. As we enter the century of biology, the world needs transformational technologies that can help us understand the full picture of how biology unfolds in daily life and we are delighted to be backing a company that is doing just that.”